Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial
Hyung Duk Kim, Ji-Yeun Chang, Byung Ha Chung, Chan-Duck Kim, Sang-Ho Lee, Yeong Hoon Kim, Chul Woo Yang
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Ann Transplant 2021; 26:e927984 :: DOI: 10.12659/AOT.927984
Available online: 2020-11-30, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication.
The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
This randomized controlled trial aimed to investigate the effect of everolimus (EVL) with low-dose tacrolimus (Tac) on the development of post-transplantation diabetes mellitus (PTDM) in kidney transplantation (KT).
MATERIAL AND METHODS Seventy-seven kidney transplant patients from 4 transplant centers were included. Patients were randomized to the “EVL group” (n=38) and the “TAC group” (n=39). The target Tac trough level was 2 to 5 ng/mL in the EVL group and 5 to 10 ng/mL in the TAC group.
RESULTS The 1-year cumulative incidence of PTDM in all patients was 7.8%, and no difference was found between the 2 groups (P=0.0819). Insulin resistance measured with the homeostatic model assessment for insulin resistance showed a significant increase only in the TAC group (1.11 to 1.30, P=0.0492). Allograft rejection rate and estimated glomerular filtration rate (eGFR) follow-ups every 3 months were not significantly different between the 2 groups. However, the EVL group showed a significant increase in the mean eGFR at 9 months and 12 months after KT compared to the baseline value (P=0.0242 and 0.0491, respectively).
The EVL group showed lower insulin resistance and higher allograft function in comparison to the TAC group. CONCLUSIONS
EVL-based immunosuppressive therapy with lower Tac exposure could be a safer alternative for maintenance treatment.
Keywords: Diabetes Mellitus; Graft Rejection; Kidney Transplantation